Xwell, INC

XWELL, Inc. has entered into a definitive agreement to divest its XpresSpa and XpresTest businesses to Express Wellness Group, LLC for $13 million, aiming to refocus on the national security sector.

XWELL Inc. has amended its prior 8-K filing to formally disclose its board's decision to hold annual "Say-on-Pay" advisory votes, aligning with stockholder preference.

XWELL, Inc. announced fiscal year 2025 financial results, reporting $29.2 million in revenue, reduced operating expenses, and strategic expansions in wellness and biosecurity.

XWELL, Inc. completed a private placement raising $31.3 million through the issuance of Series H Convertible Preferred Stock and Warrants, while simultaneously eliminating its Series G Preferred Stock.

XWELL, Inc. announced a $31.3 million private placement of convertible preferred stock and warrants, with proceeds primarily used to repurchase $9 million in existing debt and for working capital.

XWELL, Inc. stockholders reelected directors, ratified auditors, approved executive compensation, and authorized a reverse stock split and significant share issuance at the 2025 Annual Meeting.

XWELL, Inc. reported recurring losses and substantial doubt about its ability to continue as a going concern, despite securing new senior secured convertible notes and improving operating losses.

XWELL, Inc. reported a significant increase in net loss and revenue decline for the second quarter and first half of 2025, raising substantial doubt about its ability to continue as a going concern despite regaining Nasdaq compliance.

XWELL Inc.'s Q1 2025 revenue decreased by 20% year-over-year, driven by lower XpresTest and XpresSpa revenue, while the company addresses going concern doubts and Nasdaq compliance.

XWELL Inc. saw a revenue increase in Q3 2024, driven by growth in its testing segment and the acquisition of Naples Wax Center, despite an overall operating loss.

XWELL Inc. saw a revenue increase in the second quarter of 2024, driven by growth in its testing segment and the acquisition of Naples Wax Center, despite an overall operating loss.

XWELL Inc. saw a 24% increase in revenue in the first quarter of 2024, primarily driven by growth in the XpresTest segment and the addition of Naples Wax Center, despite an overall operating loss.

XWELL, Inc. reports increased net losses and significant asset impairments for 2025, but a recent $31.3 million capital raise alleviates going concern doubts and funds strategic wellness expansion.

XWELL, Inc. amends its original Form 10-K filing to include Part III information and updated certifications due to the absence of a definitive proxy statement.

XWELL, Inc. reports a 13% increase in total revenue for 2024, driven by Naples Wax acquisition and XpresSpa's touchless locations, while addressing going concern doubts and material weaknesses in internal controls.

XWELL Inc. has filed an amendment to its annual report to include required information on directors, executive compensation, and updated certifications from its principal executive and financial officers.

XWELL Inc. has filed an amendment to its annual report on Form 10-K to correct signatory errors in the certifications required by Sections 302 and 906 of the Sarbanes-Oxley Act of 2002.

XWELL Inc.'s 10-K filing reveals a significant revenue decrease due to the decline of its XpresTest segment, alongside strategic moves to expand its wellness services beyond airports.

XWELL, Inc. Director Robert Weinstein received a grant of 100,000 restricted stock units, vesting 30 days post-grant.

XWELL, Inc. Director Michael Lebowitz acquired 100,000 restricted stock units, increasing his beneficial ownership to 211,122 shares.

XWELL, Inc. President and CEO Ezra Ernst was granted 100,000 restricted stock units, vesting 30 days post-grant, contingent on continued employment.

XWELL, Inc. Director Bruce Bernstein was granted 100,000 restricted stock units, vesting 30 days post-grant, contingent on a recently closed securities purchase agreement.

XWELL, Inc. Director Gaelle Sandra Wizenberg was granted 100,000 restricted stock units, increasing her beneficial ownership.

XWELL, Inc. President and CEO Ezra Ernst was granted 70,000 restricted stock units, aligning executive incentives with shareholder interests.

XWELL, Inc. will hold its 2025 Annual Meeting to vote on proposals including a reverse stock split, board classification, and significant equity issuances to maintain Nasdaq listing and secure financing.

XWELL, Inc. files a supplement to its proxy statement to correct language regarding a proposed reverse stock split aimed at increasing its share price to meet Nasdaq's minimum bid requirement.

XWELL, Inc. issued a supplement to its proxy statement, correcting the voting requirement for its Board Classification Proposal ahead of the September 16, 2025 Annual Meeting.

XWELL, Inc. announces its 2025 Annual Meeting of Stockholders, seeking approval for a reverse stock split to address Nasdaq's minimum bid price requirement and other key corporate governance proposals.

XWELL Inc. is holding a special meeting to vote on proposals including authorizing stock issuance, classifying the Board of Directors, amending the equity incentive plan, ratifying the accounting firm, and adjourning the meeting if necessary.

XWELL, Inc. is convening a special meeting of stockholders to vote on proposals including authorizing share issuance related to a recent securities purchase agreement, classifying the board of directors, amending the equity incentive plan, ratifying the auditor, and adjourning the meeting if necessary.

Bruce Bernstein, a significant shareholder and Chairman of XWELL, Inc., has entered into a Support Agreement with Express Wellness Group, LLC, outlining voting commitments related to a proposed sale of the company's equity interests.

A group of investors led by American Ventures LLC and Dominari Holdings Inc. has disclosed a beneficial ownership interest in XWELL, Inc., capped at 4.99% due to regulatory limitations.

Iroquois Capital Management LLC, Richard Abbe, and Kimberly Page have collectively reported beneficial ownership of 5.14% of XWELL, Inc. common stock as of June 1, 2026.